Fluidigm (FLDM) vs. Pacific Biosciences (PACB) Financial Review

Fluidigm (NASDAQ: FLDM) and Pacific Biosciences (NASDAQ:PACB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Volatility and Risk

Fluidigm has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500. Comparatively, Pacific Biosciences has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Fluidigm and Pacific Biosciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fluidigm 0 1 0 0 2.00
Pacific Biosciences 0 2 0 0 2.00

Fluidigm currently has a consensus target price of $6.10, suggesting a potential upside of 5.35%. Pacific Biosciences has a consensus target price of $5.40, suggesting a potential upside of 100.74%. Given Pacific Biosciences’ higher probable upside, analysts clearly believe Pacific Biosciences is more favorable than Fluidigm.

Earnings & Valuation

This table compares Fluidigm and Pacific Biosciences’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fluidigm $101.94 million 2.21 -$60.53 million ($1.19) -4.87
Pacific Biosciences $93.47 million 3.80 -$92.18 million ($0.87) -3.09

Fluidigm has higher revenue and earnings than Pacific Biosciences. Fluidigm is trading at a lower price-to-earnings ratio than Pacific Biosciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

94.0% of Fluidigm shares are held by institutional investors. Comparatively, 59.4% of Pacific Biosciences shares are held by institutional investors. 4.7% of Fluidigm shares are held by company insiders. Comparatively, 13.4% of Pacific Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Fluidigm and Pacific Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fluidigm -55.66% -98.85% -12.49%
Pacific Biosciences -105.22% -91.11% -58.10%

About Fluidigm

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell genomics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

About Pacific Biosciences

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit